Background
Methods
Study subjects and specimen collection
HPV genotyping and cervical histopathology
Statistical analysis
Results
HPV infection according to cervical pathology status
Cervical Pathology status (total no. diagnosed) | HPV positive rate no. (%) | Single-type infection no. (%) | Multiple-type infection no. (%) | ||
---|---|---|---|---|---|
Two HPV genotypes | Three HPV genotypes | Four or more HPV genotypes | |||
Cervical intraepithelial neoplasia (CIN) | |||||
CIN grade 1 (376) | 272 (72.4) | 156 (41.5) | 68 (18.1) | 36 (9.6) | 12 (3.2) |
CIN grade 2 (408) | 332 (81.4) | 208 (51.0) | 80 (19.6) | 24 (5.9) | 20 (4.9) |
CIN grade 3 (336) | 296 (88.1) | 236 (70.2) | 40 (11.9) | 20 (6.0) | 0 |
Invasive cervical cancer | |||||
Squamous cell carcinoma (440) | 416 (94.5) | 348 (79.1) | 60 (13.6) | 8 (1.8) | 0 |
Adenocarcinoma (104) | 76 (73.1) | 68 (65.4) | 8 (7.7) | 0 | 0 |
Relative distribution of HPV genotypes according to cervical pathology status
Attribution of HPV genotypes in cervical lesions
HPV Geno-types | Crude prevalence and attribution in % (95% confidence interval) | |||||
---|---|---|---|---|---|---|
Squamous cell carcinoma (440) | Adeno-carcinoma (104) | CIN3 (336) | CIN2 (408) | CIN1 (376) | ||
HPV16 | Prevalence | 48.2 (43.5–52.8) | 23.1 (16.0–32.0) | 47.6 (42.3–53.0) | 41.2 (36.5–46.0) | 21.3 (17.4–25.7) |
Attribution | 44.6 (40.0–49.3) | 20.3 (13.7–29.0) | 43.3 (38.1–48.6) | 30.7 (26.4–35.4) | 9.9 (7.3–13.3) | |
HPV52 | Prevalence | 18.2 (14.9–22.1) | 11.5 (6.7–19.1) | 21.4 (17.4–26.1) | 21.6 (17.9–25.8) | 23.4 (19.4–27.9) |
Attribution | 15.2 (12.1–18.8) | 4.2 (1.7–10.0) | 11.1 (8.2–14.9) | 14.1 (11.0–17.8) | 18.8 (15.2–23.1) | |
HPV31 | Prevalence | 10.0 (7.5–13.2) | 0.0 (0.0–3.6) | 17.9 (14.1–22.3) | 12.7 (9.9–16.3) | 10.6 (7.9–14.2) |
Attribution | 3.9 (2.4–6.1) | 0.0 (0.0–3.6) | 10.6 (7.8–14.4) | 8.6 (6.2–11.7) | 3.8 (2.3–6.2) | |
HPV33 | Prevalence | 8.2 (6.0–11.1) | 0.0 (0.0–3.6) | 6.0 (3.9–9.0) | 12.7 (9.9–16.3) | 9.6 (7.0–13.0) |
Attribution | 1.1 (0.5–2.6) | 0.0 (0.0–3.6) | 3.7 (2.2–6.3) | 2.4 (1.3–4.4) | 5.9 (3.9–8.7) | |
HPV58 | Prevalence | 8.2 (6.0–11.1) | 0.0 (0.0–3.6) | 4.8 (3.0–7.6) | 8.8 (6.4–12.0) | 10.6 (7.9–14.2) |
Attribution | 3.8 (2.4–6.0) | 0.0 (0.0–3.6) | 3.7 (2.1–6.2) | 3.2 (1.9–5.4) | 3.8 (2.3–6.2) | |
HPV51 | Prevalence | 3.6 (2.3–5.8) | 0.0 (0.0–3.6) | 6.0 (3.9–9.0) | 5.9 (4.0–8.6) | 8.5 (6.1–11.8) |
Attribution | 2.7 (1.6–4.7) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV53 | Prevalence | 7.3 (5.2–10.1) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 7.8 (5.6–10.9) | 8.5 (6.1–11.8) |
Attribution | 5.6 (3.8–8.2) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 4.2 (2.6–6.6) | 0.0 (0.0–1.0) | |
HPV59 | Prevalence | 2.7 (1.6–4.7) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 6.9 (4.8–9.7) | 4.3 (2.6–6.8) |
Attribution | 2.7 (1.5–4.7) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 3.3 (1.9–5.6) | |
HPV56 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 6.0 (3.9–9.0) | 2.0 (1.0–3.8) | 0.0 (0.0–1.0) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 6.0 (3.9–9.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV35 | Prevalence | 0.9 (0.4–2.3) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 6.4 (4.3–9.3) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV18 | Prevalence | 4.5 (3.0–6.9) | 46.2 (36.9–55.7) | 1.2 (0.5–3.0) | 0.0 (0.0–0.9) | 2.1 (1.1–4.1) |
Attribution | 4.5 (2.9–6.9) | 44.8 (35.6–54.3) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 2.1 (1.1–4.1) | |
HPV45 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 2.0 (1.0–3.8) | 0.0 (0.0–1.0) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV68 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 4.3 (2.6–6.8) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV73 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 1.2 (0.5–3.0) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV82 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 4.9 (3.2–7.4) | 3.2 (1.8–5.5) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV66 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 6.4 (4.3–9.3) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 1.2 (0.5–2.9) | |
HPV39 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 2.1 (1.1–4.1) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV83 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV81 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 1.1 (0.4–2.7) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV6 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV43 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) | |
HPV11 | Prevalence | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) |
Attribution | 0.0 (0.0–0.9) | 0.0 (0.0–3.6) | 0.0 (0.0–1.1) | 0.0 (0.0–0.9) | 0.0 (0.0–1.0) |